



Marksans Pharma Ltd.

Date: August 04, 2026

BSE Limited

Corporate Relation Department
PhirozeJeejeebhoi Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Submission of Business Responsibility and Sustainability Report for financial year 2025-26

Dear Sir/Madam,

Pursuant to provisions of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, kindly find enclosed herewith the Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.

We request you to take the aforesaid on records.

Thanking You.

For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Encl.: As Above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W),
Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: companysecretary@marksanspharma.com

www.marksanspharma.com

Annexure - F

Annexure to the Report of the Board of directors BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT 2025-26



SECTION A: GENERAL DISCLOSURES

I. Details of the listed entity

Sr. No.	Particulars	Details
1.	Corporate Identity Number (CIN) of the Listed Entity	L24110MH1992PLC066364
2.	Name of the Listed Entity	MARKSANS PHARMA LIMITED
3.	Year of incorporation	1992
4.	Registered Office address	11 th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053
5.	Corporate address	11 th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053
6.	E-mail id	companysecretary@marksanspharma.com
7.	Telephone	(022) 4001 2000
8.	Website	www.marksanspharma.com
9.	Financial Year for which reporting is being done	April 01, 2025 to March 31, 2026
10.	Name of the Stock Exchange(s) where shares are listed	National Stock Exchange of India Limited BSE Limited
11.	Paid-up Capital	Rs. 45,31,63,746
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Name: Harshavardhan Panigrahi Designation: Company Secretary Phone No.: (022) 4001 2000 E-mail ID: companysecretary@marksanspharma.com
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements taken together).	Standalone
14.	Name of assurance provider	-
15.	Type of assurance obtained	-

II. Products/services

16. Details of business activities (accounting for 90% of the turnover):

Sr. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1.	Pharmaceutical Formulation	Research, manufacturing and sales of generics, speciality, OTC and Rx pharmaceutical products in pain management, upper respiratory, CVS, CNS, gastrointestinal, anti- diabetic, anti-infective, anti-allergic, oncology, etc.	100

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

Sr. No.	Product/Service	NIC Code	% of total Turnover contributed
1.	Solid Orals, Tablets, Capsules (including Soft Gelatin Capsules), Ointments, Liquids and Creams.	2100	100

**III. Operations****18. Number of locations where plants and/or operations/offices of the entity are situated:**

Location	Number of plants	Number of offices	Total
National	2	2	4
International	2	4	6

19. Markets served by the entity:**a) Number of locations**

Locations	Number
National (No. of States)	-
International (No. of Countries)	50+

b) What is the contribution of exports as a percentage of the total turnover of the entity?

100%

c) A brief on types of customers

The Company serves a broad customer base across key therapeutic areas. These products address the needs of a wide range of patients, through a comprehensive distribution network that includes wholesalers, distributors, retail chains, pharmacy stores, hospitals and government institutions. Furthermore, the Company extends its global presence by exporting products to international markets through both its subsidiaries and third-party distributors.

IV. Employees**20. Details at the end of Financial Year:****a) Employees and workers (including differently abled):**

Sr. No	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
Employees						
1.	Permanent (D)	1159	999	86.20	160	13.80
2.	Other than Permanent (E)	72	53	73.61	19	26.39
3.	Total employees (D + E)	1231	1052	85.46	179	14.54
Workers						
4.	Permanent (F)	526	526	100	0	0
5.	Other than Permanent (G)	478	360	75.31	118	24.69
6.	Total workers (F + G)	1004	886	88.25	118	11.75

b) Differently abled Employees and workers:

Sr. No	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
DIFFERENTLY ABLED EMPLOYEES						
1.	Permanent (D)	0	0	0	0	0
2.	Other than Permanent (E)	0	0	0	0	0
3.	Total differently abled employees (D + E)	0	0	0	0	0
DIFFERENTLY ABLED WORKERS						
4.	Permanent (F)	0	0	0	0	0
5.	Other than Permanent (G)	0	0	0	0	0
6.	Total differently abled workers (F + G)	0	0	0	0	0



21. Participation/Inclusion/Representation of women:

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	8	2	25%
Key Management Personnel	2	0	0

22. Turnover rate for permanent employees and workers (for the past 3 years):

	FY (2025-26) (Turnover rate in current FY)			FY (2024-25) (Turnover rate in previous FY)			FY (2023-24) (Turnover rate in the year prior to the previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	25.17	6.38	22.29	14.77	17.99	15.32	15	3	18
Permanent Workers	12.31	0	11.40	12.57	0	12.57	12	0	12

V. Holding, Subsidiary and Associate Companies (including joint ventures)

23. Names of holding / subsidiary / associate companies / joint ventures:

Sr. No	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1.	Marksans Pharma (UK) Limited	Subsidiary	100	No
2.	Marksans Holdings Limited	Step down Subsidiary	100	No
3.	Bell, Sons & Co. (Druggists) Limited	Step down Subsidiary	100	No
4.	Relonchem Limited	Step down Subsidiary	100	No
5.	Marksans Pharma Inc.	Subsidiary	100	No
6.	Time-Cap Laboratories Inc.	Step down Subsidiary	100	No
7.	Custom Coatings Inc.	Step down Subsidiary	100	No
8.	Marksans Realty LLC	Step down Subsidiary	100	No
9.	Marise Ann Inc.	Step down Subsidiary	100	No
10.	Nova Pharmaceuticals Australasia Pty. Ltd.	Subsidiary	60	No
11.	Nova Pharmaceuticals NZ Limited	Step down Subsidiary	100	No
12.	Access Healthcare for Medical Products LLC	Subsidiary	100	No
13.	Marksans Pharma GmbH	Subsidiary	100	No
14.	Marksans Pharma (Europe) Limited	Subsidiary	100	No
15.	Marksans (Canada) Inc.	Subsidiary	100	No

VI. CSR Details

- 24.** i. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes
- ii. Turnover (in Rs.): 1341.47 crores
- iii. Net worth (in Rs.): 1,652.31 crores



VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redressal policy)	FY2025-26			FY2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	The Company reaches out to daily wage laborers, people below poverty line and other economically backward and underprivileged people in the peripheral area of its operating locations and address their food/nutritional and healthcare needs through Company's CSR initiatives. https://www.marksanspharma.com/pdf/CSR-Poolicy.pdf	Nil	NA	-	Nil	NA	-
Investors (other than shareholders)	Yes https://www.marksanspharma.com/investor-contact.html	Nil	NA	-	Nil	NA	Nil
Shareholders	Yes. https://www.marksanspharma.com/pdf/shareholders-grievance-redressal-policy.pdf	Nil	NA	-	2	Nil	-
Employees and workers	Yes. The Company has in place policies/procedures to address employees/workers grievances. These policies/procedures are internally made available to employees/workers. Besides, the Company has in place Human Rights Policy, POSH Policy and Whistle Blower Policy. https://www.marksanspharma.com/codes-policies.html	Nil	NA	-	Nil	NA	-
Customers	Yes. https://www.marksanspharma.com/adverse-event.html	Nil	NA	-	Nil	NA	-
Value Chain Partners	Yes. https://www.marksanspharma.com/adverse-event.html	Nil	NA	-	Nil	NA	-



26. Overview of the entity's material responsible business conduct issues:

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications.

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1.	Governance	Risks & Opportunity	Risk Companies that do not have effective corporate governance practices are often prone to fraud and mismanagement. Poor corporate governance practices weaken Company's ability to capitalise business opportunities, thereby resulting in financial losses. This may further lead to a loss of stakeholder confidence and trust as well as increased Government/regulatory oversight/sanctions/ fines. Opportunity Strong corporate governance will result in increased stakeholder confidence and trust, higher ESG ratings, and stronger brand equity.	Implementing checks and balances to have appropriate controls and oversight responsibilities Instituting a Board and Committee structure and implementing board effectiveness measures in line with the stakeholders' long-term interests.	Negative Positive
2.	Business Ethics	Risks	Non-adherence to and non-compliance with ethical standards can put pharma companies at risk of fines, penalties, damaged reputation, business disruption, regulatory sanctions and erosion of trust and market capital.	Establishing processes and controls to strengthen compliance with the Company's established codes of conduct as well as applicable policies, followed by periodic review. Institutionalising effective whistleblower and grievance redressal mechanisms. Creating a culture of following the highest standards of governance.	Negative
3.	Talent attraction And retention	Opportunity	People are the biggest asset. Attracting and retaining the right talent fuels organisational growth.		Positive



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
4.	Regulatory Compliance	Risk	Regulatory guidelines and requirements heavily regulate the manufacturing of products, including manufacturing quality standards. Periodic inspections are conducted on the Company's manufacturing sites, and if the regulatory and quality standards and systems are not found adequate, it could result in observations. This might impact company's ability to meet patient demand and generate value for the stakeholders.	Creating a strong ethical organisational culture with a focus on transparency and compliance. Regularly carrying out risk assessments and audits to identify areas of potential exposure to compliance related risks. Compliance training.	Negative
5	Return on Equity/Return to Shareholders	Opportunity	ROE reflects a company's profitability, financial health, and business resilience. Strong ROE helps a business attract investors, gain greater access to capital, and create value for stakeholders.		Positive
6	Resource Efficiency	Opportunity	Focusing on how efficiently and effectively company uses natural resources and raw materials during its manufacturing and business activities.		Positive
7	Diversity, Equity and Inclusion	Opportunity	Promoting diversity, inclusion and equity in Company, and providing fair and equal remuneration and advancement opportunities to all employees. Ensuring there is no discrimination based on race, ethnicity, caste, colour, age, sex, disability, sexual orientation and the socioeconomic status of an individual. This will enhance organizational performance because it brings together people with varying views and perspectives. This, in turn, leads to better talent attraction and retention, increases greater employee engagement and results in higher efficiency. Diversity also results in better innovation and problem-solving skills and improves talent attraction.		Positive



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
8	Waste Management	Risks & Opportunity	Risks Disposal of wastewater and other wastes without proper treatment leads to legal action by central & state pollution control boards and local regulatory agencies as well as may have adverse consequences on the environment. Opportunity Wastewater treatment helps in conservation of water resources thereby mitigating water related risks. Implementing waste management plans i.e. Reduce, Reuse and Recycle conserves resources and minimizes operational expenditure and brings about positive impact on environment.	Implement water conservation measures by deployment of water efficient equipment and processes. Ensure treatment and reuse of wastewater in various activities to reduce dependency on freshwater resources. Recycling of waste reduces dependency on natural resources. Ensure compliance with waste management rules. Adopt measures to reduce waste generation during manufacturing and packaging of products. Ensure sustainable waste management practices such as waste reused, waste recycled, co-processed and safely disposed.	Negative Positive



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
9	Occupational Health & Safety	Risks & Opportunity	Risks Exposure of employees and workers to toxic or hazardous chemicals, solvents and active pharmaceutical ingredients may lead to several occupational related health diseases. Operations in the Company may involve working with heavy equipment and may pose threats of higher temperatures, chemical and physical hazards. Opportunity Ensuring safe and healthy work environment boosts employee's morale which in turn increase operational efficiency & productivity, reduce absenteeism & turnover rates, improve quality control practices by adopting safe material handling practices.	Identify the potential hazards at workplace such as chemical exposure, equipment operation risks, ergonomic issues and mitigate the risks by following appropriate safety practices. Conduct regular training programs on health and safety. Prepare and implement emergency preparedness plan. Ensure compliance with health & safety related laws, regulations and guidelines and Company's health and safety manual and policy. Monthly review of EHS performance metrics and safety campaigns are carried out. Ensure PPE is mandatory to all employees and workers while entering plant premises. Conduct health & safety and fire safety audits to identify and mitigate health & safety related risks.	Negative Positive



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
10	Supply Chain Management	Risks & Opportunity	Risks Disruption of supply chain could potentially impact the supply and sales of products in a timely manner. Delay in supply of products to patients and health care providers may affect the treatment process. Non-availability of products in a timely manner affects the brand value and reputation of the Company. Opportunity Efficient supply chain management system can streamline operations, reduce redundancies, effective logistics and inventory management practices. Strategic collaborations in supply chain management builds strong relationship with logistic partners, suppliers, distributors, and other partners. Optimization of resources in supply chain management minimizes operational expenditure and resources of the Company.	Evaluate the suppliers on reliability, quality and compliance with the regulatory standards. Conduct regular audits of suppliers to ensure adherence to quality and safety standards. Implement digital solutions for tracking and monitoring of supply chain management for better visibility, forecasting and real time monitoring of inventory and logistics. Diversify the suppliers to mitigate the risks associated with supply chain disruptions. Develop contingency plans for timely supply of products from alternate production sites or warehouses in case of potential supply chain disruptions.	Negative Positive



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
11	Research & Development	Opportunity	Opportunity Company's research & development activities such as new product development, new process development for finished dosage form, testing and defining quality of products, setting up specifications of developed products, current regulatory updates and conforming to the requirements, create competitive edge and facilitate in rapid expansion of business into new geographies and markets and generate additional revenue and reputation of the Company. Development of innovative pharmaceutical products addressing the unmet medical needs shows the commitment of the Company to deliver exceptional services promoting well-being of patients.		Positive
12	Product Quality & Safety	Risks & Opportunity	Risk Non-compliance with stringent regulatory requirements enforced by global health authorities such as US FDA, UK MHRA, Australian TGA and others can result in imposition of fines, product recalls and suspension of manufacturing licenses. Any lapses in quality control mechanisms and testing may pose a severe risk to patient health.	Adhere to Good Manufacturing Practice (GMP) compliance across all operations of the Company. Adopt pharmacovigilance processes, quality control standards and Standard Operating Procedures (SOPs) for all manufacturing processes including production, testing and packaging of products. Implement the risk mitigation plans for the potential product quality and safety risks in the life cycle of the products. Ensure regular testing of product prior to dispatch. Conduct periodic audits to ensure quality and safety of the product in line with the quality control standards.	Negative



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
			Opportunity Adhering to stringent product quality and safety standards help in getting regulatory approvals and provides access for market entry in various geographies. Fulfilling the stringent quality and safety requirements enhance the reputation and trust of the Company thereby leading to higher acceptance and demand for products.		Positive
13	Cybersecurity & Data Privacy	Risks	Risk Cyber-attacks may lead to theft of confidential information such as patient data, clinical results data, proprietary research and intellectual property rights etc. and hampers business growth, incurs financial loss and negatively affects the brand value and reputation of the Company. Inadequate prevention, detection, and remediation of data security threats can lead to disruption of operations, and negatively affects the reputation of the Company.	Implementation of strong IT management system with multiple controls, multi-factor authentication and protection systems such as anti-virus and firewalls to ensure data security. Implementation of strict access controls mechanisms to ensure only authorized personnel can access the confidential information. Ensure regulatory compliance. Develop an incident response plan and appropriate procedure for responding to cybersecurity incidents. Conduct regular training programs for employees on end point & network security controls and best practices to mitigate potential IT threats. Proactive monitoring and analysis of any new vulnerabilities and threats through regular scanning of systems and networks.	Negative



Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
14	Risk Management	Opportunity	Opportunity Robust risk management framework for proactive identification and mitigation of business risks help in achieving business resilience of the Company. Mitigation of enterprise related risks in timely manner improves operational efficiency and productivity of the Company.		Positive
15	Access to new markets and affordability of medicines	Opportunity	Opportunity Expanding access to underserved markets present a strong growth opportunity by increasing sales, revenue, and market share. Enhancing the availability and affordability of medicines strengthen brand reputation and supports better public health outcomes. These efforts also align with global health priorities, government tenders, and inclusion in national health programs, further driving business growth.		Positive



SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Policy and management processes									
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes								
b. Has the policy been approved by the Board? (Yes/ No)	Yes, the Company has developed comprehensive policies covering these principles, and some of the policies have been approved by the Board as per relevant statutory requirements.								
c. Web Link of the Policies, if available	http://marksanspharma.com/codes-policies.html Some of the Company's codes/policies/procedures are available on the Company's website in the above link in compliance with applicable regulatory requirements. Other codes/policies/procedures are internally made available to employees/workers/other stakeholders concerned.								
2. Whether the entity has translated the policy into procedures. (Yes / No)	Yes								
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes. Some of the policies relevant to value chain partners extend to them.								
4. Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Rainforest Alliance Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	The Company adheres to cGMP standards and norms of international health regulatory authorities such as USFDA, UKMHRA, Australian TGA, WHO, etc. Additionally, the Company's plants have also undergone Sedex Members Ethical Trade Audit (SMETA) covering labour standards, health & safety, environment and business ethics and Supplier Compliance Audit Network (SCAN) audits.								
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	1. To increase use of recycled packaging materials. 2. To explore avenues for using renewable energy in the plants. 3. To reduce NOx, SOx and Particulate Matter air emissions. 4. To reduce scope 1 and scope 2 greenhouse gas emissions. 5. To increase waste recovery through recycling.								
6. Performance of the entity against specific commitments, goals and targets along-with reasons in case the same are not met.	1. Use of recycled packaging materials increased by over 400%. 2. There is considerable reduction in NOx and Particulate Matter air emissions. 3. There is considerable reduction in Scope 1 greenhouse gas emission. 4. Use of recycled waste water and other materials has increased.								
Governance, leadership and oversight									
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements. Refer to the Chairman's address in the Annual Report.									
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy(ies).	Mr. Mark Saldanha Chairman & Managing Director								
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Currently Mr. Mark Saldanha, Chairman & Managing Director oversees the sustainability related issues.								



Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
----------------------	--------	--------	--------	--------	--------	--------	--------	--------	--------

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Performance against above policies and follow up action					Yes					Annually/Biennially								
Compliance with statutory requirements of relevance to the principles, and rectification of any non-compliances					Yes					Whenever required								
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No) If yes, provide name of the agency.	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9	No. The Company internally reviews the working of its codes/policies/ procedures.								

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
The entity does not consider the principles material to its business (Yes/No)									
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/human and technical resources available for the task (Yes/No)									Not Applicable
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									



SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.



Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

The Company has in place policies and procedures to ensure a high level of governance and ethics, transparency and accountability in business transactions. The Company has also in place a whistle blower policy under which directors and employees can report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct. During the year, the Company has not received any complaints about unethical practices.

Essential Indicators

1. Percentage coverage by training and awareness programs on any of the principles during the financial year:

Segment	Total number of training and awareness programs held	Topics / principles covered under the training and its impact	% age of person in respective category covered by the awareness programs
Board of Directors	1	The Company conducts familiarization programmes for its Directors on an annual basis covering their roles, functions, responsibilities and duties.	100
Key Managerial Personnel	1	KMPs are imparted professional training through programmes conducted by respective professional bodies such as ICAI and ICSI.	100
Employees other than BOD and KMPs	2	Employees undergo orientation programme during which they are apprised of the HR manuals and policies, company's codes of conduct and various policies. During the said orientation, the Company also conducts training programme covering their roles, functions, responsibilities and duties. The above orientation programme is conducted when an employee joins the Company as well as once every year.	100



Segment	Total number of training and awareness programs held	Topics / principles covered under the training and its impact	% age of person in respective category covered by the awareness programs
Workers	2	Workers undergo orientation programme during which they are apprised of the HR manuals and policies, company's codes of conduct and various policies. During the said orientation, the Company also conducts training programme covering their roles, functions, responsibilities and duties. The above orientation programme is conducted when a worker joins the Company as well as once every year.	100

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	Nil	-	-	-	-
Settlement	Nil	-	-	-	-
Compounding fee	Nil	-	-	-	-

Non-Monetary				
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	None	-	-	-
Punishment	None	-	-	-

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed:

Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
Not Applicable	

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide web-link to the policy:

Yes. Marksans' Bribery and Facilitation Payment Policy emphasize on zero tolerance approach to bribery and corruption. The policy provides information and guidance on how to recognize and deal with bribery and corruption issues. It guides the employees to act professionally, fairly and with utmost integrity in all business dealings and relationships, wherever the Company operates. <https://www.marksanspharma.com/pdf/anti-corruption-policy.pdf>



5. Number of Directors/KMPs/Employees/Workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY 2025-26	FY 2024-25
Directors	Nil	Nil
KMPs		
Employees		
Workers		

6. Details of complaints with regard to conflict of interest:

	FY 2025-26		FY 2024-25	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of Directors	Nil	-	Nil	-
Number of complaints received in relation to issues of Conflict of Interest of KMPs	Nil	-	Nil	-

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest:

Not Applicable

8. Number of days of accounts payables (Accounts payable *365)/ Cost of goods/services procured) in the following format:

	FY 2025-26	FY 2024-25
Number of days of accounts payables	97	116

9. Open-ness of business:

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics	FY 2025-26	FY 2024-25
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	Nil	Nil
	b. Number of trading houses where purchases are made from	Nil	Nil
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	Nil	Nil
Concentration of Sales	a. Sales to dealers / distributors as % of total sales	7.04	11
	b. Number of dealers / distributors to whom sales are made	27	17
	c. Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	87	75
Share of RPTs in	a. Purchases (Purchases with related parties / Total Purchases)	Nil	Nil
	b. Sales (Sales to related parties / Total Sales)	90	87
	c. Loans & advances (Loans & advances given to related parties / Total loans & advances)	Nil	Nil
	d. Investments (Investments in related parties / Total Investments made)	100% (investments are only in subsidiaries)	100% (investments are only in subsidiaries)



Leadership Indicators

1. Awareness programs conducted for value chain partners on any of the principles during the financial year:

Total number of awareness programs held	Topics / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programs
Nil		

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If yes, provide details of the same:

Yes. The Company has in place policies and procedures to ensure a high level of governance and ethics, transparency and accountability in business transactions. The Company has also in place a whistle blower policy under which directors and employees can report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct and policies. The Company has also in place a comprehensive Code of Conduct for Directors and Senior Management. Every Board member discloses the names of the entities or arrangements in which they are interested which is brought to the attention of the Board. The Company does not enter into any business dealings with the Directors and KMPs, or anybody or individuals, where they have interest, that may have any potential conflict with the interest of the Company.



Businesses should provide goods and services in a manner that is sustainable and safe

With strong R&D capability, the Company manufactures quality products that meet the standards of major health authorities globally. The Company has a relentless focus on Quality Control and Quality Assurance. Strict adherence to cGMP norms as well as our efforts towards continuous improvement of product, process and the skill of work force enables us to improve our offerings to our customers and consumers on a regular basis. The Company makes optimum utilization of resources in its manufacturing processes.

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively:

	Current Financial Year (FY 2025-26)	Previous Financial Year (2024-25)	Details of improvements in environmental and social impacts
R&D	-	-	
Capex	-	-	

*Note: The Company is planning to install solar panels to generate clean energy for its plants in Goa.

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes. Raw Materials/formulations are sourced from suppliers approved by regulatory authorities.

b. If yes, what percentage of inputs were sourced sustainably?

Majority of raw materials/formulations are sourced from sustainable suppliers.

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for

a) Plastics (including packaging) –

The waste generated is given to the authorized scrap dealer Re-processor.

b) E-waste –

E-waste generated is given to Authorized recycler.



c) Hazardous waste –

Hazardous waste (including Other Hazardous Waste as ETP Sludge, Date Expiry Products, OFF specification products) generated such as used / spent oil is given to the authorized recycler for recycling and the process waste & residue generated is sent to the authorized cement industry for co processing.

d) Other waste –

NA

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No) – Yes

If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? - Yes.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? - No

If yes, provide details in the following format:

NIC Code	Name of Product / Service	% of total Turnover contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link
-	-	-	-	-	-

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same:

Name of Product / Service	Description of the risk / concern	Action Taken
NA	-	-

3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry):

Indicate input material	Recycled or re-used input material to total material	
	FY 2025-26	FY 2024-25
None	In pharmaceutical Industry, we can't use recycled or reused input materials in the manufacturing process due to contamination issues as well as the nature of products.	

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and safely disposed, as per the following format:

	FY 2025-26			FY 2024-25		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	0	283.578	0	0	68.762	0
E-waste	0	0.766	0	0	0.510	0
Hazardous waste	0	38.500	808.530	0	1.000	773.350
Other waste	0	0	4.958	0	0	0

**5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category:**

Indicate product category	Reclaimed products and their packaging materials as % of total products sold in respective category
None	-



Businesses should respect and promote the well-being of all employees, including those in their value chains

The Company is committed to ensuring safety, sound health and overall wellbeing of the employees at all the workplaces. The Company provides equal opportunity in employee recruitment irrespective of caste, creed, gender, race and religion. The Company does not employ child labor, forced labor, or any form of involuntary labor. It provides a healthy work environment for its employees.

The Company is fully committed to uphold and maintain dignity of women working in the Company and has zero tolerance towards any actions which may fall under the ambit of sexual harassment at workplace. To ensure this, the Company has in place a Prevention of Sexual Harassment Policy.

As on March 31, 2026, the Company has 160 women employees out of the total permanent employee strength of 1685 (These include workers). No complaint pertaining to child labor, forced labor or involuntary labor was reported during the year. Further, no complaint related to sexual harassment of woman at the workplace was received.

Safety and skill upgradation training is imparted to the employees periodically.

Essential Indicators**1. a. Details of measures for the well-being of employees:**

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent employees											
Male	999	999	100%	999	100	-	-	-	-	-	-
Female	160	160	100%	160	100	160	100	-	-	-	-
Total	1159	1159	100%	1159	100	160	100	-	-	-	-
Other than Permanent employees											
Male	53	53	100%	53	100	-	-	-	-	-	-
Female	19	19	100%	19	100	19	100	-	-	-	-
Total	72	72	100%	72	100	19	100	-	-	-	-

b. Details of measures for the well-being of workers:

Category	% of workers covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent workers											
Male	526	526	100%	526	100%	-	-	-	-	-	-
Female	0	0	-	0	-	-	-	-	-	-	-
Total	526	526	100%	526	100%	-	-	-	-	-	-
Other than Permanent workers											
Male	360	360	100%	360	100%	-	-	-	-	-	-
Female	118	118	100%	118	100%	118	100%	-	-	-	-
Total	478	478	100%	478	100%	118	100%				



c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format –

	FY 2025-26	FY 2024-25
Cost incurred on well-being measures as a % of total revenue of the company	0.05%	0.05%

2. Details of retirement benefits, for Current FY and Previous Financial Year:

Benefits	FY 2025-26			FY 2024-25		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100	100	y	100	100	y
Gratuity	100	100	y	100	100	y
ESI	39.00	84.50	y	40.79	42.25	y
Others – please specify	-	-	-	-	-	-

3. Accessibility of workplaces:

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard

Yes

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web link to the policy:

Yes

<https://www.marksanspharma.com/pdf/human-rights-policy.pdf>

5. Return to work and Retention rates of permanent employees and workers that took parental leave:

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	100%	100%	100%	100%
Female	100%	100%	100%	100%
Total	100%	100%	100%	100%

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If yes, give details of the mechanism in brief:

Yes

	Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers	Yes
Other than Permanent Workers	
Permanent Employees	
Other than Permanent Employees	

The organization has a Whistle Blower policy in place which provides all employees and workers an opportunity to raise any issues/ grievances anonymously, where the identity of the whistleblower is kept confidential. A dedicated email ID has been created at an organizational level, to which the employee and workers can write their concerns. A dedicated single point contact (SPOC) is assigned to look into all matters independently and fairly.



Marksans Pharma has established a well-placed process for addressing employee grievances. An employee with a grievance can reach out to his immediate superior as the first point of contact. In case of no resolution, the respective business HR is the next point of contact, responsible for investigation and resolution in a fair & transparent manner.

For POSH-related matters, the employee is expected to raise it with the HR team or to the dedicated email ID for the Internal Committee. This can be escalated to the Chairperson of the Internal Committee. The final level of escalation is to the HR Head of the organization.

7. Membership of employees and workers in association(s) or Unions recognized by the listed entity:

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employees	1159	0	0	1349	0	0
- Male	999	0	0	1196	0	0
- Female	160	0	0	153	0	0
Total Permanent Workers	526	0	0	491	0	0
- Male	526	52	9.88	491	90	18.33
- Female	0	0	0	0	0	0

8. Details of training given to employees and workers:

Category	FY 2025-26					FY 2024-25				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Male	999	999	100	0	0	1196	1196	100	0	0
Female	160	160	100	0	0	153	153	100	0	0
Total	1159	1159	100	0	0	1349	1349	100	0	0
Workers										
Male	526	526	100	0	0	491	491	100	0	0
Female	0	0	100	0	0	0	0	0	0	0
Total	526	526	100	0	0	491	491	100	0	0

9. Details of performance and career development reviews of employees and workers:

Category	FY 2025-26			FY 2024-25		
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	% (D / C)
Employees						
Male	999	999	100	1196	1196	100
Female	160	160	100	153	153	100
Total	1159	1159	100	1349	1349	100
Workers						
Male	526	526	100	491	491	100
Female	0	0	100	0	0	0
Total	526	526	100	491	491	100



10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?

- Yes, the Company has an Occupational Health and Safety Management system implemented at our site covering the following but not limited to:
 1. Occupational Safety and Health Policy
 2. OS&H Organizational Setup
 3. Education and Training
 4. Employee Participation in OS&H Management
 5. Motivational and Promotional Measures for OS&H
 6. Safety Manual and Rules
 7. Compliance of Statutory Requirements
 8. Accident reporting, analysis, investigation and implementation of recommendation.
 9. Risk Assessment including Hazard Identification
 10. Safety inspections
 11. First aid facility - Occupational Health Centre
 12. Personal Protective Equipment
 13. Ventilation, Illumination and Noise
 14. Work Permit System
 15. Fire Prevention, Protection and Fighting System
 16. Hazardous waste Treatment and Disposal
 17. Emergency Preparedness Plans

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

- The Company has a process for Risk Management which is essential for preventing incidents, injuries, occupational disease, emergency preparedness and business continuity. There is a structured Risk Assessment and Management process which is regularly reviewed, and mitigation plans are put in place to reduce the risk. For all the activities including routine or non-routine, hazards are identified by a trained cross functional team and risk assessment is done through standard operating procedures (SOP) which is referred to before starting any activity. Identified hazards and associated risks are addressed through operational control measures using hierarchy of control approach.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)

- Yes, we have Safety Suggestion Schemes for employees/workers to report work related hazards and Suggestion box is provided at prime location. Also, we have Grievance Committee to address any work related hazards.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

Yes

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category*	FY 2025-26	FY 2024-25
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0	0
	Workers	0	0
Total recordable work-related injuries	Employees	0	0
	Workers	0	0
No. of fatalities	Employees	0	0
	Workers	0	0
High consequences for work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	0

*Including in the contract workforce

**12. Describe the measures taken by the entity to ensure a safe and healthy workplace:**

The Company undertakes periodic internal and external audits to assess the safety practices and procedures. The Company endeavors to prevent negative health impact on the employees through the provision of medical facilities and medical insurance benefits.

13. Number of Complaints on the following made by employees and workers:

	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	0	0		0	0	
Health & Safety	0	0		0	0	

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100%. Occupational Health and Safety audit is conducted once in three years through competent person authorized by Inspectorate of Factories & Boilers, Govt. of Goa.
Working Conditions	100%. An industrial hygiene survey is conducted through competent person authorized by Inspectorate of Factories & Boilers, Govt. of Goa which includes illumination, noise and ventilation of working conditions. Further, safety audit and Hygiene study was conducted in January 2025.

15. Provide details of any corrective action taken or underway to address safety related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions:

Not Applicable

Leadership Indicators**1. Does the entity extend any life insurance or any compensatory package in the event of death of :****(A) Employees (Y/N)**

Yes, Company has medical insurance scheme which covers the employees & their families. The Company also has in place a group accidental policy for the employees of the Company.

(B) Workers (Y/N)

Yes, Covered under Employee State Insurance Corp. Scheme & Medical insurance scheme.

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners:

- The Company reviews and checks monthly statutory dues deducted and deposited by the value chain partners.
- The Company also conducts monthly audit and verifies statutory registers such as wage register, muster roll, online challan, etc of its value chain partners.

3. Provide the number of employees / workers having suffered high consequences for work-related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Employees	Nil	Nil	NA	NA
Workers	Nil	Nil	NA	NA



4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)

Yes

5. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	NIL
Working Conditions	NIL

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners:

Not Applicable.



Businesses should respect the interests of and be responsive to all their stakeholders

The company provides its highest attention to the needs of disadvantaged and marginalized stakeholders and has mapped its internal and external stakeholders.

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity:

Marksans Pharma believes in partnering with its various stakeholders to build shared value and uses a structured approach of stakeholder identification. The Company's stakeholders include both individuals and organizations, within and outside the Company, who are significantly impacted by its business operations. Marksans ongoing engagements are designed to determine the needs and priorities of stakeholders, communicate the Company's efforts to fulfill their expectations, and provide speedy resolution of grievances. Marksans uses a variety of structured engagement channels to gain insights into stakeholder views and concerns.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group:

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
1. Employees and workers	No	Telephones, SMSs, E-mails, Notice Board, Personal Meetings, Website, etc.	Quarterly, Monthly (need based)	- Talent management - Employee engagement - Learning and development - Productivity - Work-life balance - Staff welfare and Health & Safety - Remuneration and employee benefits



Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
2. Suppliers	No	Telephones, SMSs, E-mails, Personal Meetings, Website, etc.	Monthly, Quarterly and Annually (need based)	- Fair contractual terms and adherence thereto - Organizational ESG consciousness - Transparent, ethical and long-term business relations - Regular exchange of technical know-how
3. Distributors	No	Telephones, SMSs, E-mails, Personal Meetings, Website, etc.	As per prevalent need	As per prevalent need
4. End Customers	Yes	Telephones, SMSs, E-mails, Website, etc.	Monthly, Quarterly and Annually (need based)	- Effective customer grievance redressal mechanism - Maintaining customer data privacy and security - Suitability of products and service - Transparent and fair advice - Providing quality products
5. Shareholders	No	E-mails, newspapers, website, stock exchanges, investors presentation, investors calls, shareholders meeting	Quarterly, annually and event based	- Market outlook - Business strategy - Operational efficiency - Long-term business performance - ESG/Market risks and opportunities in business - Technology in business
6. Regulators	No	E-mail, Physical Documents, Physical visits	Need based	- Compliance with rules and regulations - Corporate governance framework - Long-term business performance - Financial performance - Prudent business practices



Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board:**
 - The Company has always maintained a constant and proactive engagement with our key stakeholders that enables the Company to better communicate its strategies and performance. Continuous engagement helps align expectations, thereby enabling the Company to better serve its stakeholders. The Board is kept abreast of various developments and feedback on the same is sought from the Directors.
2. **Whether stakeholder consultation is used to support the identification and management of environmental and social topics (Yes / No). If so, provide details of instances as to how the input received from stakeholders on these topics was incorporated into policies and activities of the entity:**

- Yes.

Marksans Pharma has established channels for active engagement with all stakeholder groups. It is through this continued practice that the Company is offering competitive edge with the brand trust. We interact with critical stakeholders on a regular basis to ensure that our business is aligned with the stakeholder interests in a sustainable manner while being a profitable proposition. Based on such discussions with the investment community, we have aligned our goals on environmental management and amended our Policies and internal systems for environmental management.

3. **Provide details of instances of engagement with, and actions taken to address the concerns of vulnerable/ marginalized stakeholder groups:**

Marksans Pharma has fostered an active engagement channel with end customers for addressing any grievances relating to our products and assisting them in every way possible.



Businesses should respect and promote human rights

Marksans believes that all its employees live with social and economic dignity and freedom regardless of nationality, gender, race, economic status or religion. All its business associates, like suppliers, service providers and customers, should be treated likewise and also they should not suffer in any respect due to any action or inaction of the Company. Therefore, Marksans ensure that they uphold the spirit of human rights. Marksans believes business should support the protection of internationally proclaimed human rights and make sure to not be complicit in human right abuses. The Company has in place a policy on the protection of human rights. During the year, the Company has not received any complaints about human rights violation.

Essential Indicators

1. **Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:**

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / workers covered (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers covered (D)	% (D / C)
Employees						
Permanent	1159	1159	100%	1349	1349	100%
Other than permanent	72	72	100%	124	124	100%
Total Employees	1231	1231	100%	1473	1473	100%
Workers						
Permanent	526	526	100%	491	491	100%
Other than permanent	478	478	100%	693	693	100%
Total Workers	1004	1004	100%	1184	1184	100%



2. Details of minimum wages paid to employees and workers, in the following format:

Category	FY 2025-26					FY 2024-25				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Permanent	1159	99	8.54	1060	91.46	1349	193	14.31	1156	85.69
Male	999	79	7.91	920	92.09	1196	163	13.62	1033	86.38
Female	160	20	12.5	140	87.5	153	30	19.61	123	80.39
Other than Permanent	72	62	86.11	10	13.89	124	124	100	0	0
Male	53	45	84.91	8	15.09	93	93	100	0	0
Female	19	17	89.48	2	10.52	31	31	100	0	0
Workers										
Permanent	526	196	37.26	330	62.74	491	41	8.35	450	91.65
Male	526	196	37.26	330	62.74	491	41	8.35	450	91.65
Female	0	0	0	0	0	0	0	0	0	0
Other than Permanent	478	478	100	0	0	693	693	100	0	0
Male	360	360	100	0	0	603	603	100	0	0
Female	118	118	100	0	0	90	90	100	0	0

3. Details of remuneration/salary/wages:

a. Median remuneration / wages:

	Male		Female	
	Number	Median remuneration /salary/wages of respective category	Number	Median remuneration/ salary/wages of respective category
Board of Directors (BOD)	2	4,52,28,552.00	1	70,69,164.00
Key Managerial Personnel	2	1,13,77,612.00	0	-
Employees other than BOD and KMP	1260	2,48,890.71	193	2,51,674.90
Workers	727	2,29,113.60	26	1,65,990.21

* Median remuneration for workers and employees other than BOD& KMP who are in payroll for more than 90 days have been taken in calculation.

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY 2025-26	FY 2024-25
Gross wages paid to females as % of total wages	8.91%	9.20%

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes

The Company has a Whistle Blower policy in place to encourage employees to report issues without fear of retaliation, discrimination, or disadvantage. Through designated channels, the employees may report their concerns to the Chairman of the Company's Audit Committee, or the Company Secretary. The employees may further report their grievances to the HR team. Additionally, POSH Members serve as the focal point for resolving issues related to discrimination and its effects.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues:

The Organization has multiple policies and platforms to address the employee grievances related to human rights. These are as under:

- Human Resource (HR) Assistance:** Every geography/business facility of the Company has dedicated HR personnel who can be reached out by respective employees to raise any concerns or grievances with respect to any human rights issue, or otherwise. In case the issue remains unresolved, an escalation matrix is defined to enable employees to reach out to the next level authorities.



- ii. **Whistle Blower (WB) Policy:** The organization has a WB policy in place which provides all employees with an option and opportunity to raise any issues/grievances anonymously, where the identity of the whistle blower is kept confidential.
- iii. **Prevention of Sexual Harassment Guidelines (POSH):** With an aim to provide a safe and equal opportunity to both the genders, the organization has in place the guidelines for POSH. The Organization aims to create awareness from time to time so that any untoward situation of harassment is witnessed, one can reach out to the Internal Committee of the Organization. Employees can also reach out to the HR team alternatively to report the matter. An Internal committee is formed for each plant/office as prescribed by POSH Act to conduct investigation and take necessary action, as and when required.

6. Number of Complaints on the following made by employees and workers:

Category	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0	0	-	0	0	-
Discrimination at workplace	0	0	-	0	0	-
Child Labour	0	0	-	0	0	-
Forced Labour/Involuntary Labour	0	0	-	0	0	-
Wages	0	0	-	0	0	-
Other human rights related issues	0	0	-	0	0	-

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2025-26	FY 2024-25
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	NIL	NIL
Complaints on POSH as a % of female employees / workers	NIL	NIL
Complaints on POSH upheld	NA	NA

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases:

To safeguard the complainant against any adverse consequences, the Company maintains utmost confidentiality of the Complainant. All related parties against whom the Complaint has been reported are sensitized of any retaliatory action against the complainant. In case any incident of retaliation is observed or brought to notice of the management, Company takes appropriate action on the reported matter and ensures that the complainant does not undergo adverse consequences.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Not applicable

10. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labor	The Company does not employ child labor, forced labor, involuntary labor, or any other sort of discriminatory hiring practices. Marksans Pharma complies with all relevant legal requirements. Currently, no external audits are carried out.
Forced/involuntary labor	
Sexual harassment	
Discrimination at workplace	
Wages	
Others – please specify	



11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above:

NA

Leadership Indicators

1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints:

Not Applicable

2. Details of the scope and coverage of any Human rights due diligence conducted:

At present, no such exercise has been conducted in the reporting period.

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes

4. Details on assessment of value chain partners:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Sexual Harassment	-
Discrimination at workplace	-
Child Labor	-
Forced Labor/Involuntary Labor	-
Wages	-
Others – please specify	-

5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above:

Not Applicable



Businesses should respect and make efforts to protect and restore the environment

The Company continuously endeavors to protect the environment through all possible ways. Company's processes are more resource efficient, use renewable energy sources and minimize release of waste in the environment. Emissions/Wastes generated by the Company are within the permissible limits and during the year, the Company has not received any show cause or legal notice on environment issue. The Company's plants are in compliance with environmental regulations.

Essential Indicators

1 Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:

Parameter	FY 2025-26 (MJ)	FY 2024-25 (MJ)
From renewable sources		
Total electricity consumption (A)	0	0
Total fuel consumption (B)	0	0
Energy consumption through other sources (C)	0	0
Total energy consumed from renewable sources (A+B+C)	0	0



Parameter	FY 2025-26 (MJ)	FY 2024-25 (MJ)
From non-renewable sources		
Total electricity consumption (D)	126689814	110157473.56
Total fuel consumption (E)	17046100	20246248
Energy consumption through other sources (F)	120510773	31814446
Total energy consumed from non-renewable sources (D+E+F)	264246687	162218167.56
Total energy consumed (A+B+C+D+E+F)	264246687	162218167.56
Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations) MJ/Rs.	0.01969819842	0.01381316573
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total energy consumed / Revenue from operations adjusted for PPP)	0.40066135587	0.28538000401
Energy intensity in terms of physical output (MJ/Ton of Product)	31822.57	28369.73
Energy intensity (optional) – the relevant metric may be selected by the entity	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - <https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND>)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency:

No

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any:

No

3. Provide details of the following disclosures related to water, in the following format:

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)		
i. Surface water	0	0
ii. Groundwater	598	210
iii. Third party water	177436	123141.80
iv. Seawater / desalinated water	0	0
v. Others	0	67458
Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v)	178034	190809.80
Total volume of water consumption (in kiloliters)	178034	190809.80
Water intensity per rupee of turnover (Total water consumption / Revenue from operations)	0.00001327150	0.00001624779
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total water consumption / Revenue from operations adjusted for PPP)	0.00026994224	0.00033567942
Water intensity in terms of physical output (KL/Ton of Product)	21.44	33.37
Water intensity (optional) – the relevant metric may be selected by the entity	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - <https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND>)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

**4. Provide the following details related to water discharged:**

Parameter	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kilolitres)		
i. To Surface water		
• No treatment	0	0
• With treatment – please specify level of treatment	58361	53995
ii. To Groundwater		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
iii. To Seawater		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
iv. Sent to third parties		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
v. Others		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
Total water discharged (in kilolitres)	58361	53995

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation:

Yes, the ETP treated water is used for Gardening purpose.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:**Air Emission (Consolidated)**

Parameter	Please specify unit	FY 2025-26	FY 2024-25
NOx	g/kw-hr	342.34	519.57
SOx	kg/hr	61.04	6.54
Particulate matter (PM)	g/kw-hr	517.66	758.19
Persistent organic pollutants (POP)	NA	NA	NA
Volatile organic compounds (VOC)	NA	NA	NA
Hazardous air pollutants (HAP)	NA	NA	NA
Others – please specify	NA	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

Yes,

M/s. Sadekar Enviro Engineering Pvt. Ltd

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	1164.72	19912.486
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	30290.73	1530.493
Total Scope 1 and Scope 2 emission intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	MT/ Rs.	0.0000023448	0.0000018259



Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	MT/Revenue adjusted to PPP	0.00004769401	0.00003772325
Total Scope 1 and Scope 2 emission intensity in terms of physical output (MT/Ton of Product)	(MT/Ton of Product)	3.78	3.75
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - <https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND>)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency?

No

(Y/N) If yes, name of the external agency.

8. Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details:

Yes, we have an energy management policy in place and we monitor the targets annually.

9. Provide details related to waste management by the entity, in the following format:

Parameter	FY 2025-26	FY 2024-25
Total Waste generated (in metric tonnes)		
Plastic waste (A)	283.578	114.502
E-waste (B)	0.696	0.511
Bio-medical waste (C)	4.978	1.770
Construction and demolition waste (D)	0	0
Battery waste (E)	0	0
Radioactive waste (F)	0	0
Other Hazardous waste. Please specify, if any. (G)	515.100	0
Other Non-hazardous waste generated (H) Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)	660.852	436.860
Total (A+B + C + D + E + F + G + H)	1465.204	553.643
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations)	0.00000010922	0.00000004714
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP)	0.00000222160	0.00000097398
Waste intensity in terms of physical output (MT/Ton of Product)	0.17	0.09
Waste intensity (optional) – the relevant metric may be selected by the entity	-	-

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Category of waste		
i. Recycled	111.189	68.762
ii. Re-used	0	0
iii. Other recovery operations	0	0
Total	111.189	68.762

For each category of waste generated, total waste disposed of by nature of disposal method (in metric tons)

i. Incineration	0	0
ii. Landfilling	0	0
iii. Other disposal operations	1463.59	801.65
Total	1463.59	801.65

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - <https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND>)

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.



Yes. By Hazardous Waste Management Systems

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such waste:

Hazardous Waste disposal is done through GSPCB authorized vendor as per the Environment Protection Act 1986 guidelines. A manifest system (form 10 and form 9) as per rule 19 for disposal of hazardous waste is endorsed by dispatchers, transporters and receiver of hazardous waste. The endorsed copy is submitted to GSPCB on the official website

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

Sr. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
---------	--------------------------------	--------------------	---

Not Applicable

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
-----------------------------------	----------------------	------	---	--	-------------------

Not Applicable since we have the Consent issued by GSPCB.

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Sr. No.	Specify the law / regulation / guidelines which were not complied with	Provide details of the non- compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
---------	--	--	---	---------------------------------

The Company is in compliance with all applicable laws as per mandatory requirements.

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kiloliters):

For each facility / plant located in areas of water stress, provide the following information:

- Name of the area - Not Applicable
- Nature of operations - Not Applicable



iii. Water withdrawal, consumption and discharge in the following format:

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)		
i. Surface water	NA	NA
ii. Groundwater		
iii. Third party water		
iv. Seawater / desalinated water		
v. Others		
Total volume of water withdrawal (in kiloliters)		
Total volume of water consumption (in kiloliters)		
Water intensity per rupee of turnover (Water consumed / turnover)		
Water intensity (optional) – the relevant metric may be selected by the entity		
Water discharge by destination and level of treatment (in kiloliters)		
1. Into Surface water	NA	NA
• No treatment		
• With treatment – please specify level of treatment		
2. Into Groundwater		
• No treatment		
• With treatment – please specify level of treatment		
3. Into Seawater		
• No treatment		
• With treatment – please specify level of treatment		
4. Sent to third parties		
• No treatment		
• With treatment – please specify level of treatment		
5. Others		
• No treatment		
• With treatment – please specify level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

NA

2. Please provide details of total Scope 3 emissions and their intensity, in the following format:

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 3 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	-	-
Total Scope 3 emissions per rupee of turnover	MT/Rs. mn	-	-
Total Scope 3 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N):

No

3. With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities:

Not Applicable



4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along with summary)	Outcome of the initiative
1.	Upgradation & Separation of existing STP from ETP	Presently ETP and STP are clubbed as one unit, but problems are encountered below. 1) Final treated / Recycled Water is not clear and remains turbid, though the Ph and other parameters are within limits. 2) Due to mixing of Effluents and Sewage water, biomass increases and remains on higher side @70% (Limit is 30 to 40%) thus increasing the load and more consumption of treatment chemicals. 3) Increased power consumption	1) The cost of chemicals used for treatment will be reduced. 2) Savings in power bills. 3) Hazardous Sludge will be reduced by reducing the disposal cost. 4) Saving in cost of additional tanker requirement for disposing of excess effluents. 5) Biomass of ETP water will be maintained within limits. 6) The quality of treated water will be improved. 7) Requirement of additional tankers to dispose of the excess effluents will be eliminated

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link:

Yes.

Marksans Business Continuity is the creation of a plan to resume its critical business processes after a disruption. The goal of the plan is to prevent loss of life, reduce property damage and minimise the impact on the overall business functions. The overall objective of the plan is to provide the information and procedures necessary to rapidly respond to a disaster or emergency situation, notify necessary trained personnel, assemble business recovery teams, rapidly recover services to clients, and to rapidly resume normal business functions.

6. Disclose any significant adverse impact on the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard?

None

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts:

None



Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

The Company is a member of Bombay Chamber of Commerce and does participate in presenting industry-related issues to the Government.

Essential Indicators

1. a. Number of affiliations with trade and industry chambers/ associations:

One

- b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to:

Sr. No	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
1.	Bombay Chamber of Commerce	National



2. Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on adverse orders from regulatory authorities:

Name of authority	Brief of the case	Corrective action taken
Not Applicable		

Leadership Indicators

1. Details of public policy positions advocated by the entity:

Sr. No	Public policy advocated	Method resorted for such advocacy	Whether information is available in public domain? (Yes/No)	Frequency of Review by Board (Annually/ Half yearly/ Quarterly / Others – please specify)	Web Link, if available
Not Applicable					



Businesses should respect and make efforts to protect and restore the environment

The Company is continuously exploring various focus areas for its CSR activities and is also in the process of identifying NGOs working in the areas of health and education to support them in their endeavors.

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
Not Applicable					

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

Sr. No.	Name of Project for which R&R is ongoing	State	District	Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In INR)
Not Applicable						

3. Describe the mechanisms to receive and redress grievances of the community:

The Company engages its community members through in-person meetings.

**4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:**

Parameter	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/ small producers	4.86	9.40
Sourced from other than MSMEs within India	65.70	68.88
Imports	29.44	21.72

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost:

Location	FY2025-26	FY2024-25
Rural	0	0
Semi-urban	0	0
Urban	74.77	72.52
Metropolitan	25.23	27.48

Note: Place categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan and based Census 2011.

Leadership Indicators**1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):**

Details of negative social impact identified	Corrective action taken
Not Applicable	

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

Sr. No	State	Aspirational District	Amount spent (In INR)
None			

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)

No, since we have to source our materials from suppliers approved by global health regulatory bodies only.

(b) From which marginalized /vulnerable groups do you procure?

Not Applicable

(c) What percentage of total procurement (by value) does it constitute?

Not Applicable

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:

Sr. No	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/No)	Benefit shared (Yes / No)	Basis of calculating benefit share
Not Applicable				



5. Details of corrective actions taken or underway, based on any adverse order intellectual property related disputes wherein usage of traditional knowledge is involved:

Name of authority	Brief of the Case	Corrective action taken
Not Applicable		

6. Details of beneficiaries of CSR Projects:

Sr. No	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1.	Organized free health check-up camps and distributed free medicines and other medical supplies to underprivileged people in the state of Goa.	-	-
2.	Distribution of free food items to daily wage labourers, people below poverty line and other economically backward people who do not have regular income.	-	-
3.	Building and upkeep of public garden/park and tree plantation in Verna Industrial area, Goa.	-	-
4.	Contributions towards women and child development, professionalizing Anganwadis and national nutrition mission in Goa.	-	-
5.	Various other projects undertaken from time to time as per CSR policy of the Company in the areas of education, healthcare and disaster management.	-	-



Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback:

Every endeavor is made to achieve maximum customer satisfaction by manufacturing world-class quality products and ensuring fair treatment in all customer dealings. The Company complies with all applicable labeling standards. Customers' complaints are attended on a priority basis.

There are no customer complaints/ consumer cases pending resolutions at the end of the financial year. There is no case against the Company regarding unfair trade practice, irresponsible advertising, anti-competitive behavior during the last five years. The Company conducts consumer survey periodically.

2. Turnover of products/services as a percentage of turnover from all products/services that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	We comply with relevant laws and regulations of the countries we operate in with respect to disclosure of information on environmental and social parameters relevant to the products. 100% of our formulation products, representing 100% of our overall revenue, carry information about
Safe and responsible usage	safe and responsible usage on product labelling and package inserts. Further, based on the legal requirements, guidelines and customer requirements in the countries of our operations, we
Recycling and/or safe disposal	include instructions on recycling and/ or safe disposal of products.

**3. Number of consumer complaints in respect of the following:**

	FY 2025-26		Remarks	FY 2024-25		Remarks
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year	
Data privacy	Nil	Nil	-	Nil	Nil	-
Advertising	Nil	Nil	-	Nil	Nil	-
Cyber-security	Nil	Nil	-	Nil	Nil	-
Delivery of essential services	Nil	Nil	-	Nil	Nil	-
Restrictive Trade Practices	Nil	Nil	-	Nil	Nil	-
Unfair Trade Practices	Nil	Nil	-	Nil	Nil	-
Other	Nil	Nil	-	Nil	Nil	-

4. Details of instances of product recalls on account of safety issues:

	Number	Reasons for recall
Voluntary recalls	Nil	-
Forced recalls	Nil	-

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy:

Yes. The Company has a framework on cyber security and risks related to data privacy as a part of Risk Management Policy.

<https://www.marksanspharma.com/pdf/risk-management-policy.pdf>

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services:

None

7. Provide the following information relating to data breaches:

- Number of instances of data breaches: Nil
- Percentage of data breaches involving personally identifiable information of customers: Nil
- Impact, if any, of the data breaches: NA

Leadership Indicators**1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available):**

www.marksanspharma.com

2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services:

At Marksans, sustainable innovation is a core part of Company's DNA. The Company continues to work together with our partners and customers to explore new ways to incorporate sustainable materials across our product range and bring them to new markets, including increased communications. The Company conducts consumer survey periodically.

3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services:

Issues that are bound to arise in any customer/supplier relationship, there is continual communication maintained with customers. This helps to identify problems before they become serious and allows both the parties to work towards mutually beneficial solutions. The Company focuses on quality and customer service and continues to strengthen our relationship and position as a trusted partner.

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable)

No

Did your entity carry out any survey about consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)

Yes